We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Cancer Identified By Scanning Surface Veins with Lasers

By Biotechdaily staff writers
Posted on 17 Sep 2007
A new technology for cancer detection that eliminates the need for drawing blood has recently been developed.

Researchers from the University of Purdue (West Lafayette, IN, USA) collaborated with cancer and biotechnology specialists from the Mayo Clinic (Rochester, MN, USA) to develop technology to detect tumor cells within the human body. More...
By shining a laser on surface veins, such as those on the wrist and inside the cheek, researchers are able to reveal and count circulating tumor cells.

Optical imaging provides high resolution and chemical specificity for cancer detection, but it typically is limited from limited penetration depth, making it hard to reach tumors inside the body, according to Dr. Ji-Xin Cheng, an assistant professor of chemistry and biomedical engineering at Purdue.

The technique could provide clinicians and patients results in minutes, and save the medical industry millions of dollars in testing equipment, according to Wei He, a graduate student in the Purdue department of chemistry and the department of biomedical engineering. He worked on the project with Drs. Low and Cheng. By directly labeling tumor cells while they are in the bloodstream, some of the costs and problems associated with testing drawn blood samples can be avoided, according to Mr. He.

An article describing the technology and detection technique was published in the July 10, 2007, issue of the journal Proceedings of the [U.S.] National Academy of Sciences. The technique uses a fluorescent tumor-specific probe that labels tumor cells in circulation. When hit by a laser, which scans across the diameter of the blood vessel 1,000 times per second, the tumor cells glow and become visible. The in-vivo flow detection was performed on a two-photon fluorescence microscope in Dr. Cheng's lab. The researchers compared several methods and found two-photon fluorescence provides the best signal to background ratio. The technology is able to scan every cell that is pumped through the vessel.

The researchers have developed two labeling agents that attach to different forms of cancer. One label targets ovarian, non-small lung, kidney, and endometrial cancer, and the other targets prostate cancer. These labels would be administered through an injection. The first label has already been evaluated in humans and has no adverse side effects and could potentially be administered weekly.

The laser penetrates to a depth of 100 microns and is able to examine shallow blood vessels near the surface of the skin. Sophisticated optical technology could be incorporated into the technology platform and enable the method to reach deeper vessels that handle larger volumes of blood, according to Dr. Cheng.


Related Links:
University of Purdue
Mayo Clinic

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Influenza Virus Test
NovaLisa Influenza Virus B IgM ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.